Summary of transplant characteristics and survival in selected prospective studies of RIC HSCT in CLL
| . | Fred Hutchinson Cancer Center38 . | German CLL Study Group41,45 . | MD Anderson Cancer Center40 . | Dana Farber Cancer Institute39 . |
|---|---|---|---|---|
| Number of patients | 82 | 90 | 86 | 76 |
| Conditioning regimen | Flu/low-dose TBI | Flu/Cy ± ATG | Flu/Cy ± R | Flu/Bu |
| Donors, % (sibling/MUD) | 63/37 | 41/59 | 50/50 | 37/63 |
| Median follow-up, mo | 60 | 72 | 37 | 61 |
| Median PFS, % | 39 (5 y) | 38 (6 y) | 36 (6 y) | 43 (6 y) |
| Median OS, % | 50 (5 y) | 58 (6 y) | 51 (6 y) | 63 (6 y) |
| Early mortality, % (<100d) | <10 | <3 | <3 | <3 |
| NRM, % | 23 | 23 | 17 | 16 |
| Acute grade 3-4 GVHD, % | 20 | 14 | 7 | 17 |
| Severe chronic GVHD, % | 53 | 55 | 56 | 48 |
| . | Fred Hutchinson Cancer Center38 . | German CLL Study Group41,45 . | MD Anderson Cancer Center40 . | Dana Farber Cancer Institute39 . |
|---|---|---|---|---|
| Number of patients | 82 | 90 | 86 | 76 |
| Conditioning regimen | Flu/low-dose TBI | Flu/Cy ± ATG | Flu/Cy ± R | Flu/Bu |
| Donors, % (sibling/MUD) | 63/37 | 41/59 | 50/50 | 37/63 |
| Median follow-up, mo | 60 | 72 | 37 | 61 |
| Median PFS, % | 39 (5 y) | 38 (6 y) | 36 (6 y) | 43 (6 y) |
| Median OS, % | 50 (5 y) | 58 (6 y) | 51 (6 y) | 63 (6 y) |
| Early mortality, % (<100d) | <10 | <3 | <3 | <3 |
| NRM, % | 23 | 23 | 17 | 16 |
| Acute grade 3-4 GVHD, % | 20 | 14 | 7 | 17 |
| Severe chronic GVHD, % | 53 | 55 | 56 | 48 |
ATG, antithymocyte globulin; Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; MUD, matched unrelated donor; R, rituximab; TBI, total body irradiation.